MCID: MXD023
MIFTS: 48

Mixed Cell Type Cancer

Categories: Cancer diseases, Endocrine diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Mixed Cell Type Cancer

MalaCards integrated aliases for Mixed Cell Type Cancer:

Name: Mixed Cell Type Cancer 11 14 16
Malignant Mixed Neoplasm 11 16
Mixed Tumor, Malignant 11 43
Malignant Mixed Tumor 11 71
Mixed Neoplasm 11 71
Malignant Mixed Tumor, Not Otherwise Specified 71
Mixed Tumor, Not Otherwise Specified 71
Mixed Salivary Gland Tumor 71
Malignant Mixed Cancer 11
Mixed Tumor 11

Classifications:



External Ids:

Disease Ontology 11 DOID:154
MeSH 43 D018198
NCIt 49 C3729 C6930
SNOMED-CT 68 8145008
UMLS 71 C0026277 C0206625 C1368354 more

Summaries for Mixed Cell Type Cancer

Disease Ontology: 11 A cell type cancer that has material basis in abnormally proliferating cells derives from two germinal layers of tissue.

MalaCards based summary: Mixed Cell Type Cancer, also known as malignant mixed neoplasm, is related to uterine corpus adenosarcoma and adenomyoma. An important gene associated with Mixed Cell Type Cancer is MIR542 (MicroRNA 542), and among its related pathways/superpathways are Disease and Signal Transduction. The drugs Gemcitabine and Doxorubicin have been mentioned in the context of this disorder. Affiliated tissues include salivary gland, uterus and lymph node, and related phenotypes are Decreased viability and Increased shRNA abundance (Z-score > 2)

Related Diseases for Mixed Cell Type Cancer

Diseases related to Mixed Cell Type Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 794)
# Related Disease Score Top Affiliating Genes
1 uterine corpus adenosarcoma 32.1 PGR MME ESR1
2 adenomyoma 31.9 PGR MME KRT7 ESR1
3 uterine body mixed cancer 31.7 TP53 PTEN PPP2R1A POLE PIK3CA KRAS
4 ovarian carcinosarcoma 31.7 TP53 PPP2R1A PIK3CA PAX8 KRAS HRAS
5 carcinosarcoma 31.1 TP53 SYP PTEN PPP2R1A PIK3CA PGR
6 adenoma 31.0 TP53 SYP PIK3CA KRT7 KRAS HRAS
7 skin benign neoplasm 30.8 TP53 SERPINA3 KRT7 KRT5 HRAS
8 malignant fibrous histiocytoma 30.5 TP53 SERPINA3 KIT
9 leiomyosarcoma 30.5 TP53 SERPINA3 PGR KIT ESR1
10 sarcoma 30.4 TP53 SERPINA3 PIK3CA KRAS KIT HRAS
11 lung benign neoplasm 30.4 TP53 SYP KRT7 KRAS HRAS
12 gallbladder cancer 30.4 TP53 PTEN PIK3CA KRT7 KRAS HRAS
13 transitional cell carcinoma 30.4 TP53 PTEN KRT7 ERBB2
14 hidradenoma 30.3 MME KRT7 KRT5
15 ameloblastoma 30.3 TP53 SERPINA3 KRAS
16 pleomorphic rhabdomyosarcoma 30.3 TP53 SERPINA3 PIK3CA HRAS
17 mediastinal cancer 30.3 SYP KRT7 KIT
18 epithelial-myoepithelial carcinoma 30.3 KRT7 KRT5 KIT
19 appendix adenocarcinoma 30.3 TP53 SYP KRT7 KRAS HRAS
20 fibroma 30.3 SERPINA3 PGR KRT7 ESR1
21 lipomatosis, multiple 30.3 TP53 SERPINA3 PTEN PIK3CA KIT
22 mesenchymal cell neoplasm 30.3 TP53 SERPINA3 MME KIT
23 thymoma 30.2 TP53 SYP KRT7 KIT HRAS
24 connective tissue benign neoplasm 30.2 TP53 SERPINA3 MME KIT H2AC18
25 papillary cystadenocarcinoma 30.2 TP53 SERPINA3 KRT7
26 ceruminoma 30.2 KRT7 KRT5
27 salivary gland adenoid cystic carcinoma 30.2 TP53 SERPINA3 KRT7 KRT5 KIT
28 adenofibroma 30.2 TP53 PAX8 MME KRT7 KRAS ARID1A
29 fallopian tube carcinoma 30.1 TP53 PTEN PAX8 KRT7 ERBB2
30 exanthem 30.1 KRAS KIT HRAS H2AC18 ERBB2
31 neurofibromatosis 30.1 TP53 PTEN KRAS KIT HRAS
32 necrotizing sialometaplasia 30.1 TP53 KRT7 KRT5
33 basaloid squamous cell carcinoma 30.1 TP53 SYP KRT7 KRT5 KIT
34 obstructive jaundice 30.1 SYP SERPINA3 KRT7
35 pheochromocytoma 30.1 SYP MME KRT7 KIT HRAS ESR1
36 bladder cancer 30.1 TP53 PTEN PIK3CA KRT7 KRAS HRAS
37 krukenberg carcinoma 30.1 SYP PAX8 KRT7
38 well-differentiated liposarcoma 30.1 TP53 SERPINA3 KIT
39 lymphoma, non-hodgkin, familial 30.1 TP53 SERPINA3 PIK3CA MME H2AC18
40 sertoli-leydig cell tumor 30.1 SYP PGR KRT7
41 vaginal discharge 30.1 PGR KRT7 ESR1
42 collecting duct carcinoma 30.1 PAX8 MME KRT7
43 adenosquamous carcinoma 30.1 SERPINA3 PGR KRT7 KRT5 KRAS HRAS
44 chordoma 30.0 TP53 SERPINA3 PTEN KRT7
45 syringocystadenoma papilliferum 30.0 SERPINA3 KRT7 KRT5 HRAS
46 spindle cell sarcoma 30.0 TP53 SERPINA3 KRT7 KIT
47 ovarian serous carcinoma 30.0 TP53 PAX8 HRAS H2AC18
48 cystic teratoma 30.0 TP53 SYP PAX8 KRT7
49 papillary adenofibroma 30.0 PTEN POLE PAX8 ARID1A
50 squamous cell carcinoma 30.0 TP53 PTEN PIK3CA KRT7 KRAS HRAS

Graphical network of the top 20 diseases related to Mixed Cell Type Cancer:



Diseases related to Mixed Cell Type Cancer

Symptoms & Phenotypes for Mixed Cell Type Cancer

GenomeRNAi Phenotypes related to Mixed Cell Type Cancer according to GeneCards Suite gene sharing:

25 (show all 42)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.37 HRAS KRAS PIK3CA
2 Decreased viability GR00055-A-2 10.37 HRAS KRAS PIK3CA
3 Decreased viability GR00055-A-3 10.37 KRAS
4 Decreased viability GR00106-A-0 10.37 KRAS
5 Decreased viability GR00221-A-1 10.37 ESR1 HRAS KIT KRAS PIK3CA
6 Decreased viability GR00221-A-2 10.37 ESR1 HRAS KRAS PIK3CA
7 Decreased viability GR00221-A-3 10.37 HRAS
8 Decreased viability GR00221-A-4 10.37 ESR1 PIK3CA
9 Decreased viability GR00301-A 10.37 KIT KRAS
10 Decreased viability GR00381-A-1 10.37 KRAS
11 Decreased viability GR00386-A-1 10.37 ESR1
12 Decreased viability GR00402-S-2 10.37 ESR1 PIK3CA
13 Increased shRNA abundance (Z-score > 2) GR00366-A-1 10.25 POLE
14 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.25 KRAS
15 Increased shRNA abundance (Z-score > 2) GR00366-A-123 10.25 POLE
16 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.25 PTEN
17 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.25 PTEN
18 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.25 ERBB2
19 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.25 ARID1A ERBB2 POLE PTEN
20 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.25 ARID1A
21 Increased shRNA abundance (Z-score > 2) GR00366-A-186 10.25 ARID1A
22 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.25 ARID1A
23 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.25 POLE
24 Increased shRNA abundance (Z-score > 2) GR00366-A-207 10.25 ERBB2 POLE
25 Increased shRNA abundance (Z-score > 2) GR00366-A-213 10.25 ARID1A
26 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.25 PTEN
27 Increased shRNA abundance (Z-score > 2) GR00366-A-22 10.25 KRAS
28 Increased shRNA abundance (Z-score > 2) GR00366-A-32 10.25 ERBB2 POLE
29 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.25 PTEN
30 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.25 ARID1A
31 Increased shRNA abundance (Z-score > 2) GR00366-A-60 10.25 ERBB2
32 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.25 ERBB2 KRAS POLE PTEN
33 Increased shRNA abundance (Z-score > 2) GR00366-A-66 10.25 PTEN
34 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.25 ARID1A
35 Increased shRNA abundance (Z-score > 2) GR00366-A-82 10.25 H2AC18
36 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.25 ERBB2 POLE
37 Increased shRNA abundance (Z-score > 2) GR00366-A-87 10.25 ERBB2 POLE PTEN
38 Increased shRNA abundance (Z-score > 2) GR00366-A-91 10.25 POLE
39 Increased shRNA abundance (Z-score > 2) GR00366-A-93 10.25 PTEN
40 Increased shRNA abundance (Z-score > 2) GR00366-A-99 10.25 H2AC18
41 Decreased viability in pancreas lineage GR00235-A 9.46 ARID1A KRT7 PGR TP53
42 Reduced mammosphere formation GR00396-S 9.17 HRAS KRAS KRT7 PAX8 POLE PPP2R1A

MGI Mouse Phenotypes related to Mixed Cell Type Cancer:

45 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.39 ARID1A ERBB2 ESR1 HRAS KIT KRAS
2 neoplasm MP:0002006 10.35 ARID1A ERBB2 ESR1 HRAS KIT KRAS
3 normal MP:0002873 10.35 ARID1A ERBB2 ESR1 HRAS KIT KRAS
4 nervous system MP:0003631 10.33 ARID1A ERBB2 ESR1 HRAS KIT KRAS
5 muscle MP:0005369 10.24 ARID1A ERBB2 ESR1 HRAS KIT KRAS
6 endocrine/exocrine gland MP:0005379 10.24 ARID1A ERBB2 ESR1 HRAS KIT KRAS
7 no phenotypic analysis MP:0003012 10.21 ARID1A ESR1 HRAS KIT KRAS PAX8
8 behavior/neurological MP:0005386 10.2 ERBB2 ESR1 HRAS KIT KRAS KRT5
9 limbs/digits/tail MP:0005371 10.18 ERBB2 ESR1 KIT KRAS KRT5 PAX8
10 embryo MP:0005380 10.18 ARID1A ERBB2 ESR1 KIT KRAS PAX8
11 cellular MP:0005384 10.18 ARID1A ERBB2 ESR1 KIT KRAS KRT7
12 digestive/alimentary MP:0005381 10.11 ERBB2 ESR1 HRAS KIT KRAS KRT5
13 cardiovascular system MP:0005385 10.11 ARID1A ERBB2 ESR1 HRAS KIT KRAS
14 craniofacial MP:0005382 10.03 ARID1A ERBB2 HRAS KIT KRAS KRT5
15 immune system MP:0005387 10.03 ARID1A ESR1 KIT KRAS KRT5 MME
16 skeleton MP:0005390 9.9 ARID1A ERBB2 ESR1 HRAS KIT KRAS
17 mortality/aging MP:0010768 9.8 ARID1A ERBB2 ESR1 HRAS KIT KRAS
18 integument MP:0010771 9.44 ERBB2 ESR1 HRAS KIT KRAS KRT5

Drugs & Therapeutics for Mixed Cell Type Cancer

Drugs for Mixed Cell Type Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 95)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gemcitabine Approved Phase 2, Phase 3 95058-81-4, 122111-03-9 60750
2
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
3
Topotecan Approved, Investigational Phase 2, Phase 3 123948-87-8, 119413-54-6 60699 60700
4
Niraparib Approved, Investigational Phase 2, Phase 3 1038915-60-4 24958200
5
Pertuzumab Approved Phase 2, Phase 3 380610-27-5
6
Trastuzumab Approved, Investigational Phase 2, Phase 3 180288-69-1
7
Ifosfamide Approved Phase 3 3778-73-2 3690
8
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
9
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
10
Palifosfamide Investigational Phase 3 31645-39-3 100427
11 Antineoplastic Agents, Immunological Phase 2, Phase 3
12 Liposomal doxorubicin Phase 2, Phase 3
13 Alkylating Agents Phase 3
14 Antineoplastic Agents, Alkylating Phase 3
15
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
16
Sunitinib Approved, Investigational Phase 2 557795-19-4 5329102
17
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 43805 11947679 6857599
18
Erlotinib Approved, Investigational Phase 2 183319-69-9, 183321-74-6 176870
19
Aflibercept Approved Phase 2 862111-32-8 124490314
20
Thalidomide Approved, Investigational, Withdrawn Phase 2 50-35-1 5426
21
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239
22
Coenzyme M Approved, Investigational Phase 2 3375-50-6 598 23662354
23
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
24
Lenvatinib Approved, Investigational Phase 2 417716-92-8 9823820
25
Fulvestrant Approved, Investigational Phase 1, Phase 2 129453-61-8 17756771 104741
26
Iodine Approved, Investigational Phase 2 7553-56-2 807
27
Durvalumab Approved, Investigational Phase 2 1428935-60-7
28
Tremelimumab Approved, Investigational Phase 2 745013-59-6
29
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
30
Rucaparib Approved, Investigational Phase 2 283173-50-2 9931954
31
Olaparib Approved Phase 2 763113-22-0 23725625
32
Metformin Approved Phase 2 1115-70-4, 657-24-9 4091
33
Doxycycline Approved, Investigational, Vet_approved Phase 2 564-25-0 54671203
34
Bevacizumab Approved, Investigational Phase 2 216974-75-3 135329020
35
Pembrolizumab Approved Phase 2 1374853-91-4 254741536
36
Cisplatin Approved Phase 2 15663-27-1 2767 5702198 441203
37
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030
38
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
39
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
40
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
41
Iniparib Investigational Phase 2 160003-66-7 9796068
42
Rivoceranib Investigational Phase 2 811803-05-1 11315474
43
MK-1775 Investigational Phase 2 955365-80-7 24856436
44
Linrodostat Investigational Phase 2 1923833-60-6 121328278
45
Cediranib Investigational Phase 2 288383-20-0 9933475
46 Liver Extracts Phase 2
47
Imatinib Mesylate Phase 2 220127-57-1
48 Epothilones Phase 2
49 Epothilone B Phase 2 4456137
50 Antiviral Agents Phase 2

Interventional clinical trials:

(show top 50) (show all 69)
# Name Status NCT ID Phase Drugs
1 A Multicentric Randomized Phase II/III Evaluating TSR-042 (Anti-PD-1 mAb) in Combination With Niraparib (Parpi) Versus Niraparib Alone Compared to Chemotherapy in the Treatment of Metastatic or Recurrent Endometrial or Ovarian Carcinosarcoma After at Least One Line of Chemotherapy Recruiting NCT03651206 Phase 2, Phase 3 Niraparib;Chemotherapy Drugs
2 A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-Oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma Recruiting NCT05256225 Phase 2, Phase 3 Carboplatin;Hyaluronidase-zzxf/Pertuzumab/Trastuzumab;Paclitaxel;Trastuzumab/Hyaluronidase-oysk
3 A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary Active, not recruiting NCT00954174 Phase 3 Carboplatin;Ifosfamide;Paclitaxel
4 A Phase II Multicenter Trial of Paclitaxel and Carboplatin in Women With Advanced (IIIb, IIIc, IVa and IVb) or Recurrent (All Stages) Malignant Mixed Mullerian Tumors (MMMT) of the Uterus Completed NCT00502203 Phase 2 Carboplatin;Paclitaxel
5 Phase II Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS) Completed NCT02993705 Phase 2 Trabectedin
6 A Phase 2 Study of Sunitinib Malate in Recurrent or Metastatic Endometrial Carcinoma Completed NCT00478426 Phase 2 Sunitinib Malate
7 A Phase II Study of Oxaliplatin and Gemcitabine Followed by Radiation Therapy in the Management of Mixed Mullerian Tumors of the Uterus Completed NCT00476086 Phase 2 Gemcitabine;Oxaliplatin
8 Phase II Study Evaluating PegLiposomal Doxorubicin (PLD) and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors Completed NCT00815945 Phase 2 PegLiposomal Doxorubicin;Carboplatin
9 A Randomized Phase II Trial of Avastin (A) or Avastin and Erlotinib (AE) as First Line Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Newly Diagnosed Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors Completed NCT00520013 Phase 2 bevacizumab;erlotinib;paclitaxel;carboplatin
10 Phase II Study of Paclitaxel (TAXOL), Intraperitoneal Cisplatin and IV Avastin Followed by Avastin Consolidation for Advanced Ovarian and Peritoneal Carcinoma or Fallopian Tube Cancer Completed NCT00511992 Phase 2 Avastin;Paclitaxel;Cisplatin
11 A Phase II Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma Completed NCT00687687 Phase 2 paclitaxel;carboplatin;BSI-201 (Iniparib)
12 A Phase II Study of VEGF-Trap in Recurrent or Metastatic Gynecologic Soft-Tissue Sarcomas Completed NCT00390234 Phase 2 ziv-aflibercept
13 A Phase II Evaluation of Thalidomide (NSC #66847) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT00025506 Phase 2 Thalidomide
14 A Phase II Study of BAY 43-9006 in Advanced/Recurrent Uterine Carcinoma/Carcinosarcoma Completed NCT00238121 Phase 2 sorafenib tosylate
15 A Pilot Phase II Trial of Adjuvant Radiation Therapy "Sandwiched" Between Ifosfamide in Patients With Mixed Mesodermal Tumors Completed NCT00231842 Phase 2 Ifosfamide;Cisplatin
16 A Phase 2 Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
17 A Phase II Evaluation of Gemcitabine (NSC #613327) and Docetaxel (NSC # 628503) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT00114218 Phase 2 Gemcitabine Hydrochloride;Docetaxel
18 A Phase II Evaluation of Gleevec(TM) (NCI-Supplied Agent: STI571 [Imatinib Mesylate], NSC# 716051) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT00075400 Phase 2 imatinib mesylate
19 A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial, Epithelial Ovarian Cancer, or Carcinosarcoma Completed NCT03395080 Phase 2 Paclitaxel;300mg DKN-01;600mg DKN-01
20 A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT01247571 Phase 2 Pazopanib Hydrochloride
21 A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT01168232 Phase 2 Ixabepilone
22 A Non-randomized, Open-label, Multi-center, Phase I/II Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Copanlisib in Pediatric Patients With Relapsed/Refractory Solid Tumors or Lymphoma Recruiting NCT03458728 Phase 1, Phase 2 BAY806946
23 A Phase II Trial of Pembrolizumab Plus Olaparib for the Treatment of Patients With Persistent/Recurrent Endometrial Cancers Recruiting NCT05156268 Phase 2 Pembrolizumab;Olaparib
24 A Phase II Trial of Pembrolizumab Plus Lenvatinib for the Treatment of Patients With Advanced Uterine and Ovarian Carcinosarcomas Recruiting NCT05147558 Phase 2 Pembrolizumab;Lenvatinib
25 A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients With Advanced Solid Tumors Recruiting NCT05252416 Phase 1, Phase 2 BLU-222;Carboplatin;Ribociclib;Fulvestrant
26 A Multicenter, Open, Single Arm, Phase II Clinical Study of Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma Recruiting NCT05265793 Phase 2 Camrelizumab Combined With Apatinib
27 A Phase II Trial of Nivolumab for Recurrent/Metastatic Carcinosarcoma Recruiting NCT05224999 Phase 2 nivolumab
28 MC1365, A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer Recruiting NCT02364713 Phase 2 Gemcitabine Hydrochloride;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
29 A Phase 2 Study of the Wee1 Inhibitor AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma Recruiting NCT03668340 Phase 2 AZD1775
30 Pazopanib vs. Pazopanib Plus Gemcitabine in Patients With Relapsed or Metastatic Uterine Leiomyosarcomas or Uterine Carcinosarcomas: a Multi-center, Randomized Phase-II Clinical Trial of the NOGGO and AGO - PazoDoble - Recruiting NCT02203760 Phase 2 Pazopanib plus Gemcitabine;Pazopanib
31 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Recruiting NCT02834013 Phase 2
32 A Phase 2 Trial of ZW25 in HER2 Overexpressed Advanced Endometrial Cancers and Carcinosarcomas (ZW25-IST-2) Recruiting NCT04513665 Phase 2 ZW25
33 A Phase 2 Trial of Durvalumab [MEDI4736](Anti-PD-L1 Antibody) With or Without Tremelimumab (Anti-CTLA-4 Antibody) in Patients With Persistent or Recurrent Endometrial Carcinoma and Endometrial Carcinosarcoma Active, not recruiting NCT03015129 Phase 2 Durvalumab;Tremelimumab
34 An Open Label, Non-Randomized Multisite Phase II Trial Combining Bevacizumab, Atezolizumab and Rucaparib for the Treatment of Previously Treated Recurrent and Progressive Endometrial Carcinoma Active, not recruiting NCT03694262 Phase 2 Rucaparib;Bevacizumab;Atezolizumab
35 A Phase II Trial of IDO-Inhibitor, BMS-986205, and PD-1 Inhibitor, Nivolumab, in Patients With Recurrent or Persistent Endometrial Cancer or Endometrial Carcinosarcomas (CA017-056) Active, not recruiting NCT04106414 Phase 2 Nivolumab;BMS- 986205
36 A 3-Arm Randomised Phase II Evaluation of Cediranib in Combination With Weekly Paclitaxel or Olaparib Versus Weekly Paclitaxel Chemotherapy for Advanced Endometrial Carcinoma or for Disease Relapse Within 18 Months of Adjuvant Carboplatin-paclitaxel Chemotherapy. Active, not recruiting NCT03570437 Phase 2 Paclitaxel;Cediranib;Olaparib
37 An International Multi-centre Randomised Phase II Study to Assess the Efficacy of TAK228 in Combination With Intravenous Weekly Paclitaxel Compared With Weekly Paclitaxel Alone in Women With Advanced/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) Active, not recruiting NCT03648489 Phase 2 Paclitaxel;TAK228
38 A Phase II Study of Metformin in Combination With Doxycycline in Patients With Localized Breast, and Uterine, and Cervical Cancer Active, not recruiting NCT02874430 Phase 2 Metformin Hydrochloride;Doxycycline
39 A Phase Ib/II Single Arm Study of Cabozantinib Plus Dostarlimab in Women With Recurrent Gynecologic Carcinosarcoma Not yet recruiting NCT05559879 Phase 1, Phase 2 Cabo + Dostarlimab
40 The EPOCH Study: Phase II Open Labelled Study Investigating the Use of Single Agent Eribulin and Eribulin in Combination With Pembrolizumab in Relapsed Tubo-ovarian or Uterine Carcinosarcoma Not yet recruiting NCT05619913 Phase 2 Eribulin Mesylate;Pembrolizumab
41 Randomized Phase 2 Trial of APL-2 With Pembrolizumab vs. APL-2 With Pembrolizumab and Bevacizumab vs. Bevacizumab Alone in Patients With Recurrent Ovarian Cancer and Persistent Malignant Effusion Not yet recruiting NCT04919629 Phase 2
42 Pamiparib in Combination With Surufatinib in Patients With Platinum-resistant Ovarian Cancer Who Received Prior Poly (ADP-ribose) Polymerase (PARP) Inhibitors: a Multicenter, Single-arm, Phase Ib/II Trial Not yet recruiting NCT05494580 Phase 1, Phase 2 Pamiparib;Surufatinib
43 A Phase II Study of Adjuvant Postoperative Radiation With Cisplatin Followed by Carboplatin/Paclitaxel Chemotherapy Following Total Abdominal Hysterectomy/Bilateral Salpino-Oophorectomy (TAH/BSO) for Patients With Stage I, II and IIIa Malignant Mixed Mesodermal Tumor (MMMT) of the Uterus. Terminated NCT00505492 Phase 2 Carboplatin;Cisplatin;Paclitaxel
44 A Phase II Study of Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian Cancer Terminated NCT00322881 Phase 2 Paclitaxel;Carboplatin
45 Pilot Phase II Study of Temsirolimus in Patients With Recurrent Mixed Mesodermal and Mullerian Tumors (Carcinosarcoma) of the Uterus Terminated NCT01061606 Phase 2 temsirolimus
46 A Pilot Study of Peroral Vorinostat (SAHA) in Patients With Refractory Histone Deacetylase-positive Uterine Sarcoma Terminated NCT03509207 Phase 2 Vorinostat Oral Capsule
47 Phase II Trial of Postoperative Radiotherapy and Panitumumab in High-risk Salivary Gland Malignancies Withdrawn NCT00984217 Phase 2 Panitumumab
48 A Phase II Single Arm Study of Cabozantinib Plus Nivolumab and Ipilimumab in Women With Recurrent Gynecologic Carcinosarcoma Withdrawn NCT04149275 Phase 2 Cabozantinib;Ipilimumab;Nivolumab
49 A Phase II, Signal-Seeking Trial of the Clinical Benefit Rate Associated With Pamiparib in Subjects With Germline or Somatic BRCA1/2 High Grade Serous Ovarian Cancer or Carcinosarcoma Who Have Progressed on P-gp Substrate Chemotherapy or PARPi With the Presence of an ABCB1 Fusion and the Absence of a BRCA1/2 Reversion Withdrawn NCT03933761 Phase 2 Pamiparib
50 A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma Unknown status NCT01454479 Phase 1 Lapatinib and ixempra

Search NIH Clinical Center for Mixed Cell Type Cancer

Cochrane evidence based reviews: mixed tumor, malignant

Genetic Tests for Mixed Cell Type Cancer

Anatomical Context for Mixed Cell Type Cancer

Organs/tissues related to Mixed Cell Type Cancer:

MalaCards : Salivary Gland, Uterus, Lymph Node, Ovary, Skin, Breast, Prostate

Publications for Mixed Cell Type Cancer

Articles related to Mixed Cell Type Cancer:

(show top 50) (show all 1537)
# Title Authors PMID Year
1
Adenoid Basal Carcinoma with Adenoid Cystic Carcinoma Component of the Uterine Cervix: A Case Report and Literature Review. 62
36452999 2022
2
Lipomatous mixed tumor of the skin with cystic formation affecting the upper lip: A case report. 62
36168412 2022
3
Mixed tumor of nasal cavity: A case report. 62
36334996 2022
4
Pleomorphic Adenoma of the Palate: A Case Report. 62
36475232 2022
5
Usefulness of ultrasonography in the preoperative diagnosis of mixed tumor of the skin (chondroid syringoma): A case series with nine patients. 62
35718945 2022
6
Spatial distribution of CD34 protein in primordial odontogenic tumour, ameloblastic fibroma and the tooth germ. 62
36207782 2022
7
Cutaneous Myoepithelial Neoplasms on Acral Sites Show Distinctive and Reproducible Histopathologic and Immunohistochemical Features. 62
35354162 2022
8
Subungal Mixed Tumor Mimicking Glomus Tumor: A Case Report and Literature Review. 62
36276218 2022
9
The clinical characteristics and treatment of ovarian malignant mesoderm mixed tumor: a systematic review. 62
36114551 2022
10
Near-infrared-induced drug release from antibody-drug double conjugates exerts a cytotoxic photo-bystander effect. 62
36176626 2022
11
A rare case report of pleomorphic adenoma of the upper lip: An unusual clinical presentation. 62
36393934 2022
12
Primary laparoscopic RPLND for pure seminona metastasis: feasibility of supine and lateral approaches. 62
36037258 2022
13
Tumor cell budding in preoperative biopsies of esophageal and gastroesophageal junction carcinoma independently predicts survival in a grade-dependent manner. 62
35422326 2022
14
[Ovarian Carcinosarcoma Associated with Cowden Syndrome-A Case Report]. 62
35851351 2022
15
Ameloblastic Fibro-Odontoma. 62
35748698 2022
16
[Reconstruction of facial skin defects by the V-Y subcutaneous pedicle flap]. 62
35725315 2022
17
Gliosarcoma with osteosarcomatous component: A case report and short review illustration. 62
35278815 2022
18
Ductal and acinar components of mixed prostatic adenocarcinoma frequently have a common clonal origin. 62
35049068 2022
19
'Teratoid' Hepatoblastoma: An Intriguing Variant of Mixed Epithelial-Mesenchymal Hepatoblastoma. 62
35455609 2022
20
Proliferation in pleomorphic adenoma: Lights and shadow on this parameter, in a neoplasm showing unpredictable behavior-An immunohistochemical study and review of the literature. 62
35094844 2022
21
Evolution of superficial spreading melanoma to resemble desmoplastic melanoma: case report. 62
34286349 2022
22
Uterine Adenosarcoma in a Teen Ager. 62
35633000 2022
23
Brenner tumors of the ovary: clinical features and outcomes in a single-center cohort 62
35000896 2022
24
Characteristic of Uterine Rhabdomyosarcoma by Algorithm of Potential Biomarkers for Uterine Mesenchymal Tumor. 62
35448164 2022
25
High grade uterine adenosarcoma with sarcomatous overgrowth in a young woman amenable to primary surgical reduction: A case study and literature review. 62
35036509 2022
26
Odontogenic carcinosarcoma - A rare case report with review of literature. 62
35450233 2022
27
Predicting cancer immunotherapy response from gut microbiomes using machine learning models. 62
35875611 2022
28
The Histopathological Types and Distribution Characteristics of Gastric Mixed Tumors. 62
35785186 2022
29
Acquired chemoresistance drives spatial heterogeneity, chemoprotection and collective migration in pancreatic tumor spheroids. 62
35617275 2022
30
Combination of Adenomyoepithelioma and Adenoid Cystic Carcinoma of the Breast: A Case Report of an Uncommon Histopathological Entity. 62
35064096 2022
31
Recent Advances on Immunohistochemistry and Molecular Biology for the Diagnosis of Adnexal Sweat Gland Tumors. 62
35158743 2022
32
[Endometrioide-type cervical adenomyoma]. 62
34980438 2022
33
Clinical, Radiological and Histopathological Features of Patients With Lacrimal Gland Enlargement. 62
35014239 2021
34
Histology transformation-mediated pathological atypism in small-cell lung cancer within the presence of chemotherapy: A case report. 62
35004997 2021
35
Rare Case Report: Young Male Hard Palate Pleomorphic Adenoma. 62
34692463 2021
36
A Machine learning model trained on dual-energy CT radiomics significantly improves immunotherapy response prediction for patients with stage IV melanoma. 62
34795006 2021
37
Cutaneous adenomyoepithelioma with histopathological heterogeneity: A case report. 62
34473865 2021
38
Early and late recurrences in lymph node-negative gastric cancer: a retrospective cohort study. 62
34873937 2021
39
Apocrine mixed tumor with pilomatrical differentiation. 62
34291474 2021
40
Carcinoma Expleomorphic Adenoma of the Lacrimal Gland. 62
33710040 2021
41
Survival and prognostic factors of salivary gland malignant mixed tumor-not otherwise specified: A population-based analysis. 62
34171696 2021
42
Malignant mixed tumor of the skin on the anterior chest. 62
34240174 2021
43
Carcinoma with Triphasic Differentiation Arising from Inverted Papilloma in Sinonasal Sinus: A Rare Case with Molecular Characterization. 62
34679524 2021
44
Cytodiagnosis of chondroid syringoma-Series of three cases. 62
34174020 2021
45
Mixed Intraepithelial Neoplasia-Well-Differentiated Neuroendocrine Tumor of the Gallbladder: A Hitherto Unreported Combination. 62
33423570 2021
46
Editorial Comment to A case of mixed tumor formed by metastasis of urothelial carcinoma and malignant lymphoma to the same lymph nodes. 62
34497988 2021
47
A case of mixed tumor formed by metastasis of urothelial carcinoma and malignant lymphoma to the same lymph nodes. 62
34497987 2021
48
Effectiveness of Preoperative Embolization in Patients with Spinal Metastases: A Systematic Review and Meta-Analysis. 62
34153484 2021
49
Exenteration and Adjuvant Radiotherapy for Primary Carcinosarcoma of the Anterior Orbit: A Case Report. 62
33481539 2021
50
An atypical chondroid syringoma with malignant degeneration: Utility of comparative genomic hybridization in confirming the diagnosis. 62
33470448 2021

Variations for Mixed Cell Type Cancer

Expression for Mixed Cell Type Cancer

Search GEO for disease gene expression data for Mixed Cell Type Cancer.

Pathways for Mixed Cell Type Cancer

Pathways related to Mixed Cell Type Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 64)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.81 TP53 PTEN PPP2R1A PIK3CA KRAS KIT
2 13.71 TP53 PTEN PPP2R1A PIK3CA PGR KRAS
3
Show member pathways
13.42 TP53 PTEN PPP2R1A KRAS KIT HRAS
4
Show member pathways
13.36 ERBB2 ESR1 HRAS KIT KRAS PIK3CA
5
Show member pathways
13.04 TP53 PTEN PPP2R1A PIK3CA KIT ESR1
6
Show member pathways
13 PIK3CA PGR KRAS HRAS H2AC18 ESR1
7
Show member pathways
12.89 TP53 PTEN PPP2R1A PIK3CA KRAS KIT
8 12.71 TP53 PTEN PIK3CA KIT HRAS
9 12.69 ERBB2 ESR1 HRAS KIT KRAS PGR
10
Show member pathways
12.65 PTEN PPP2R1A PIK3CA KIT ESR1 ERBB2
11
Show member pathways
12.63 TP53 PPP2R1A PIK3CA KRAS KIT HRAS
12
Show member pathways
12.6 TP53 PIK3CA KRAS HRAS ERBB2
13
Show member pathways
12.6 TP53 PTEN PIK3CA KRAS KIT HRAS
14
Show member pathways
12.48 ERBB2 HRAS KRAS PIK3CA TP53
15
Show member pathways
12.43 TP53 PIK3CA KRAS HRAS ERBB2
16
Show member pathways
12.42 PIK3CA KRAS HRAS ESR1
17
Show member pathways
12.42 PIK3CA KRAS HRAS ESR1
18
Show member pathways
12.41 PIK3CA KRAS KIT HRAS ERBB2
19
Show member pathways
12.4 TP53 PTEN PIK3CA HRAS ESR1 ERBB2
20
Show member pathways
12.34 ERBB2 ESR1 HRAS PIK3CA
21
Show member pathways
12.33 PTEN PIK3CA KRAS HRAS
22 12.3 PTEN PIK3CA HRAS ERBB2
23
Show member pathways
12.28 PPP2R1A PIK3CA KRAS HRAS
24
Show member pathways
12.27 TP53 PTEN PIK3CA HRAS
25 12.26 HRAS KIT KRAS PIK3CA
26
Show member pathways
12.25 PIK3CA KRAS HRAS ERBB2
27 12.19 TP53 PIK3CA KRAS HRAS
28
Show member pathways
12.17 TP53 PTEN PIK3CA KRAS HRAS ERBB2
29
Show member pathways
12.16 TP53 PTEN PIK3CA HRAS
30 12.16 TP53 PTEN KRAS ESR1
31
Show member pathways
12.14 ERBB2 HRAS PIK3CA PTEN
32 12.1 TP53 PTEN KRAS ERBB2
33
Show member pathways
12.04 PIK3CA KRAS HRAS ERBB2
34
Show member pathways
12 PTEN PIK3CA KIT HRAS
35 11.98 PIK3CA KRAS KIT HRAS
36
Show member pathways
11.92 PIK3CA PGR KRAS HRAS ESR1 ERBB2
37
Show member pathways
11.91 PIK3CA KRAS KIT HRAS
38
Show member pathways
11.9 PTEN PIK3CA KRAS HRAS ERBB2
39
Show member pathways
11.85 PIK3CA KRAS HRAS
40 11.83 TP53 PIK3CA HRAS
41
Show member pathways
11.78 PIK3CA KRAS HRAS
42
Show member pathways
11.78 PIK3CA KRAS KIT HRAS
43
Show member pathways
11.77 TP53 PIK3CA KRAS HRAS
44 11.74 TP53 PTEN ESR1
45 11.74 TP53 PTEN PIK3CA KRAS HRAS ERBB2
46 11.72 TP53 PTEN PPP2R1A ESR1
47 11.71 PTEN PIK3CA HRAS
48
Show member pathways
11.71 TP53 PTEN PIK3CA PGR KRAS KIT
49
Show member pathways
11.68 PIK3CA KRAS HRAS
50
Show member pathways
11.67 PTEN KRAS HRAS

GO Terms for Mixed Cell Type Cancer

Biological processes related to Mixed Cell Type Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 fibroblast proliferation GO:0048144 9.63 TP53 HRAS ESR1
2 positive regulation of RNA polymerase II transcription preinitiation complex assembly GO:0045899 9.56 TP53 ESR1
3 regulation of long-term neuronal synaptic plasticity GO:0048169 9.43 SYP KRAS HRAS
4 positive regulation of phospholipase C activity GO:0010863 9.1 KIT HRAS ESR1

Sources for Mixed Cell Type Cancer

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....